A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.
The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.
After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.
Targetmol provides 30 monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.
Cat. No. | 製品名 | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T76687 | Ibalizumab | 680188-33-4 | 98% |
|
Ibalizumab(TMB-355) is a humanized IgG4 monoclonal antibody that acts as a CD4 receptor inhibitor, blocking the entry of HIV-1 into cells by binding to the CD4 r... | ||||
T76685 | Glofitamab | 2229047-91-8 | 98% |
|
Glofitamab (RO7082859) is a novel bivalent antibody directed against CD20-binding T cells.Glofitamab promotes T cell proliferation and activation and tumor cell ... | ||||
T76684 | Girentuximab | 916138-87-9 | 98% |
|
Girentuximab (G250) is a potent anti-carbonic anhydrase IX (CAIX) monoclonal antibody with anticancer activity for the study of uroepithelial carcinoma PET (ZiPU... | ||||
T76682 | Galcanezumab | 1578199-75-3 | 98% |
Galcanezumab
|
Galcanezumab is a humanized IgG4 monoclonal antibody targeting the CGRP ligand, which binds to the ligand calcitonin gene-related peptide. Galcanezumab can be us... | ||||
T76681 | Fresolimumab | 948564-73-6 | 98% |
Fresolimumab
|
Fresolimumab (GC1008) is a specific human anti-transforming growth factor β monoclonal antibody that binds to the active forms of human TGFβ1, TGFβ2, and TGFβ3 a... | ||||
T76674 | Cibisatamab | 1855925-27-7 | 98% |
|
Cibisatamab is a T-cell bispecific antibody that acts as a T-cell splicer.Cibisatamab targets carcinoembryonic antigen (CEA) on cancer cells and CD3 on T-cells, ... | ||||
T76673 | Bemarituzumab | 1952272-74-0 | 98% |
Bemarituzumab
|
Bemarituzumab is a novel humanized IgG1 monoclonal antibody targeting FGFR2b. Bemarituzumab prevents FGFR2b from binding to FGF and activation. Potential applica... | ||||
T76672 | Aprutumab | 1634620-63-5 | 98% |
Aprutumab
|
Aprutumab (BAY 1179470) is a human FGFR2 monoclonal antibody with affinity to FGFR2 isoforms FGFR2-IIIB and FGFR2-IIIC. Aprutumab is commonly used to synthesize ... | ||||
T76671 | Amatuximab | 931402-35-6 | 98% |
Amatuximab
|
Amatuximab (MORab-009) is a chimeric IgG1/k monoclonal antibody humanized against cell surface mesoleptin (MSLN) with antitumor activity for the treatment of sol... | ||||
T73698 | Basiliximab | 179045-86-4 | 98% |
Basiliximab
|
Basiliximab (CHI 621) is a chimeric mouse/human IgG1 monoclonal recombinant antibody against the interleukin-2 receptor. Basiliximab has good immunosuppressive a... | ||||
T73695 | Canakinumab | 914613-48-2 | 98% |
|
Canakinumab (ACZ885) is a recombinant human IL-1β-targeting monoclonal antibody.Canakinumab has been shown to inhibit human and chorioallantoic monkey IL-1β, wit... | ||||
T73689 | Daclizumab | 152923-56-3 | 98% |
Daclizumab
|
Daclizumab (Zenapax) is a humanized monoclonal antibody that specifically inhibits the alpha subunit of IL-2R-HA. Daclizumab (Zenapax) can inhibit the binding of... | ||||
T9914 | Vedolizumab | 943609-66-3 | 98% |
|
Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of Crohn's disease and ulcerative colitis. | ||||
T9918 | Daratumumab | 945721-28-8 | 98% |
|
Daratumumab is a human monoclonal antibody that targets CD38 a cell surface protein that is overexpressed on multiple myeloma MM) cells. | ||||
T38362 | Guselkumab | 1350289-85-8 | 98% |
|
Guselkumab (CNTO 1959) is a recombinant human IgG1 monoclonal antibody targeting the IL-23p19 subunit. Guselkumab binds to human cynomolgus monkey IL-23 with Kd ... | ||||
T9916 | Alirocumab | 1245916-14-6 | 98% |
Alirocumab
|
Alirocumab is a human monoclonal antibody that inhibits PCSK9. It is produced by recombinant DNA technology in Chinese hamster ovary cell suspension culture. | ||||
T78268 | Anti-Mouse NK1.1 Antibody (PK136) | 98% |
Anti-Mouse NK1.1 Antibody (PK136)
|
|
Anti-Mouse NK1.1 Antibody (PK136) is an IgG2a class antibody of murine origin targeting NK1.1, which eliminates NK1.1 and NK1.1NKT cells and inhibits NK1.1 signa... | ||||
T77751 | Imaprelimab | 2014343-04-3 | 98% |
Imaprelimab
|
Imaprelimab (PRX-003) is a humanized IgG1 κmonoclonal antibody against melanoma cell adhesion molecule (MCAM). Imaprelimab has antitumor activity and can be used... | ||||
T77750 | Rosmantuzumab | 1684393-04-1 | 98% |
Rosmantuzumab
|
Rosmantuzumab (OMP-131R10) is a humanized monoclonal antibody against R-spondin 3 (RSPO3). Rosmantuzumab has potential antitumor activity and can be used to stud... | ||||
T77749 | Upifitamab | 2254118-43-7 | 98% |
Upifitamab
|
Upifitamab is a naked antibody to upifitamab rilsodotin, which can be used to synthesize the antibody-coupled active molecule UPRI, which can be used to study ca... |